Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP-004 + PD-1 inhibitor in postoperative pancreatic cancer
NCT06496373Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XP-004 in pancreatic cancer (PC), sponsored by Ruijin Hospital. Primary endpoint: Drug related toxicity at 18 months. Started Jul 2024; status: recruiting.
02
Drugs
XP-004
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06496373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496373.